Rolf-Peter Hummel

USPTO Granted Patents = 12 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 19(Granted Patents)

Company Filing History:

Years Active: 2008-2015

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9090597 - Pyrazolone derivatives as PDE4 inhibitors (2015-07-28),

2. 8865745 - Pyrazolone derivatives as PDE4 inhibitors (2014-10-21),

3. 8829189 - Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives (2014-09-09),

4. 8754218 - Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives (2014-06-17),

5. 8557858 - (E)-N-(2-amino-phenyl)-3-{1-[4-(l-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts (2013-10-15),

6. 8354535 - Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives (2013-01-15),

7. 8304436 - Pyrazolone derivatives as PDE4 inhibitors (2012-11-06),

8. 8232297 - Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles (2012-07-31),

9. 8198295 - Benzonaphthyridines (2012-06-12),

10. 8188138 - Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors (2012-05-29),

11. 7718668 - Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives (2010-05-18),

12. 7470704 - Benzonaphthyridines (2008-12-30),

Title: Rolf-Peter Hummel: Innovator in Pharmaceutical Chemistry

Introduction

Rolf-Peter Hummel is a distinguished inventor based in Radolfzell, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of 12 patents to his name, Hummel's work has had a considerable impact on the treatment of various medical conditions.

Latest Patents

Among his latest innovations are pyrazolone derivatives that serve as inhibitors of phosphodiesterase type 4 (PDE4). One notable compound, 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione, has shown promise as an effective treatment for psoriasis and atopic dermatitis. This compound exemplifies Hummel's commitment to advancing therapeutic options for patients.

Career Highlights

Hummel has worked with prominent companies in the pharmaceutical industry, including Nycomed GmbH and Takeda GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development efforts.

Collaborations

Throughout his career, Hummel has collaborated with notable colleagues such as Christian Scheufler and Martin Feth. These partnerships have fostered an environment of innovation and have led to the successful development of various pharmaceutical products.

Conclusion

Rolf-Peter Hummel's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key figure in the field. His work continues to influence the development of effective treatments for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.